CLINICAL AND PARA-CLINICAL CHARACTERISTICS OF RECURRENT NASOPHARYNGEAL CARCINOMA: A STUDY AT K HOSPITAL
Main Article Content
Abstract
Objective: To describe some clinical and para-clinical features of patients with recurrent nasopharyngeal carcinoma at National Cancer Hospital from June 2022 to September 2024. Patients and Methods: A retrospective study was conducted on 39 patients diagnosed with recurrent nasopharyngeal carcinoma at the Head and Neck Radiation Department of K Hospital from June 2022 to September 2024. Results: The average age was 53.9 ± 10 years [39–78], with a male-to-female ratio of 2:1. Headache was the most common reason for hospital admission, accounting for 33.3%. Patients in stages III and IVa before initial treatment had a high recurrence rate, comprising 76.9% of the cases. At recurrence, the predominant stage was IVa (25.6%). The average time to recurrence was 30.3 ± 16.6 months [8.53–71.63]. Conclusion: Recurrent nasopharyngeal carcinoma is more commonly observed in middle-aged male patients, predominantly at stage IVa, and frequently occurs within the first two years after treatment.
Article Details
Keywords
Recurrent nasopharyngeal carcinoma, radiotherapy interruption, PET/CT, MRI.
References


2. Tuấn NA, Chinh HĐ, Biểu BQ, và cộng sự. Kết quả hóa xạ trị điều biến liều ung thư vòm mũi họng giai đoạn II-III. Tạp Chí Học Việt Nam. 2023;530(1B). doi:10.51298/vmj.v530i1B.6752


3. Argirion I, Zarins KR, Suwanrungruang K, et al. Subtype Specific Nasopharyngeal Carcinoma Incidence and Survival Trends: Differences between Endemic and Non-Endemic Populations. Asian Pac J Cancer Prev APJCP. 2020;21(11): 3291. doi:10.31557/APJCP.2020.21.11.3291


4. Peng Z, Wang Y, Fan R, et al. Treatment of Recurrent Nasopharyngeal Carcinoma: A Sequential Challenge. Cancers. 2022;14(17):4111. doi:10.3390/cancers14174111


5. Hiếu TĐ. Đánh giá kết quả điều trị ung thư vòm mũi họng giai đoạn tái phát hoặc di căn bằng phác đồ Gemcitabin - Cisplatin tại Bệnh viện Ung bướu Nghệ An. Tạp Chí Dược Thái Bình. Published online November 6, 2023:99-107.

6. Treatment by Cancer Type. NCCN. Accessed October 24, 2024. https://www.nccn.org/ guidelines/category_1

7. Zhang Y, Chen L, Hu GQ, et al. Gemcitabine and Cisplatin Induction Chemotherapy in Nasopharyngeal Carcinoma. N Engl J Med. 2019; 381(12): 1124-1135. doi:10.1056/ NEJMoa1905287


8. Hwang JM, Fu KK, Phillips TL. Results and prognostic factors in the retreatment of locally recurrent nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys. 1998;41(5):1099-1111. doi:10. 1016/s0360-3016(98)00164-3


9. Teo PM, Kwan WH, Chan AT, et al. How successful is high-dose (>or = 60 Gy) reirradiation using mainly external beams in salvaging local failures of nasopharyngeal carcinoma? Int J Radiat Oncol Biol Phys. 1998; 40(4): 897-913. doi:10.1016/s0360-3016 (97)00854-7


10. Ng WT, Soong YL, Ahn YC, et al. International Recommendations on Reirradiation by Intensity Modulated Radiation Therapy for Locally Recurrent Nasopharyngeal Carcinoma. Int J Radiat Oncol Biol Phys. 2021;110(3):682-695. doi:10.1016/j.ijrobp.2021.01.041

